The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index; 19 of the 49 sources its claims cite were checked for support.
Abstract
This study aimed to investigate the influence of genetic variants in neuroplasticity-related genes on antidepressant treatment phenotypes. The BDNF-TrkB signaling pathway, as well as the downstream kinases Akt and ERK and the mTOR pathway, have been implicated in depression and neuroplasticity. However, clinicians still struggle with the unpredictability of antidepressant responses in depressed patients. We genotyped 26 polymorphisms in BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 in 80 patients with major depressive disorder treated according to the Texas Medical Algorithm for 27 months at Hospital Magalhães Lemos, Porto, Portugal. Our results showed that BDNF rs6265, PTEN rs12569998, and SYN1 rs1142636 SNP were associated with treatment-resistant depression (TRD). Additionally, MAPK1 rs6928 and GSK3B rs6438552 gene polymorphisms were associated with relapse. Moreover, we found a link between the rs6928 MAPK1 polymorphism and time to relapse. These findings suggest that the BDNF, PTEN, and SYN1 genes may play a role in the development of TRD, while MAPK1 and GSK3B may be associated with relapse. GO analysis revealed enrichment in synaptic and trans-synaptic transmission pathways and glutamate receptor activity with TRD-associated genes. Genetic variants in these genes could potentially be incorporated into predictive models of antidepressant response.
Overview
CoChat Summary
TL;DR
In 80 Portuguese patients with major depressive disorder followed for 27 months on the Texas Medication Algorithm, polymorphisms in BDNF, PTEN, and SYN1 were associated with treatment-resistant depression, while MAPK1 and GSK3B were associated with relapse. Functional enrichment implicated synaptic and trans-synaptic transmission and glutamate receptor activity.
Key findings
- BDNF rs6265 CT genotype was associated with TRD (OR: 3.2; 95% CI: 0.975–10.501; p = 0.049); PTEN rs12569998 TG genotype was associated with TRD (OR: 4.231; 95% CI: 1.173–15.261; p = 0.020); SYN1 rs1142636 GG genotype was associated with TRD (OR: 6.00; 95% CI: 1.543–23.333; p = 0.006), as was the G allele (OR: 3.120; 95% CI: 1.045–9.314; p = 0.037).
- MAPK1 rs6928 C allele carriers had reduced relapse risk (OR: 0.303; 95% CI: 0.090–1.020; p = 0.048) and relapsed later than GG carriers (100 vs. 82 weeks, p = 0.022, log-rank).
- GSK3B rs6438552 GG genotype was associated with relapse (OR: 6.667; 95% CI: 1.121–39.660; p = 0.042), as was the G allele (OR: 5.600; 95% CI: 1.137–27.571; p = 0.033).
- GO analysis of TRD-associated genes showed enrichment in chemical synaptic transmission, anterograde trans-synaptic signaling, glutamate receptor signaling, neuron projections, dendrites, and ionotropic glutamate receptor complexes.
Methods
- Candidate-gene pharmacogenetic cohort study of 80 MDD patients recruited at Hospital Magalhães Lemos, Oporto, Portugal, followed for 27 months and treated according to the Texas Medication Algorithm; diagnosis used SCID-I and severity used BDI. Evaluated phenotypes included remission, TRD, time to remission, relapse, and time to relapse.
- Genotyped 26 polymorphisms in BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 using the Sequenom MassARRAY platform; 10% of samples were repeated for quality control with the same results.
- Statistical analysis used chi-square tests, odds ratios with 95% confidence intervals, Kaplan–Meier survival curves with log-rank tests, and Hardy–Weinberg equilibrium testing; Geneshot and Enrichr were used for GO and KEGG enrichment analyses.
Limitations
- The paper states the sample is small, so small effects of single SNPs may not be detected; only a few SNPs per gene were evaluated due to the target-pathway design; and because drugs with different mechanisms of action were used, each SNP could not be correlated with a specific antidepressant class.
- Evident from the text: no correction for multiple comparisons is reported despite testing 26 polymorphisms across multiple treatment phenotypes, and the findings are candidate-gene associations in a small cohort that require replication.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
17 Valid · 1 Not valid · 14 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition to the lag time between AD and clinical improvement, there are still about 30% of MDD patients who do not present improvements upon AD treatment, displaying a TRD phenotype [26].”
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 3. Discussion
What the sources say
- Partly supportedcites [26] Smith, 2013, Quest for biomarkers of treatment-resistant depression: Shifting the paradigm toward risk, Front. Psychiatry sourceExperimental — accuracy not yet measured
The Definitions of TRD section (page unavailable) describes treatment-resistant depression as major depressive disorder that has not improved after at least two adequate antidepressant trials. The Concluding Remarks (page unavailable) say treatment fails to relieve symptoms in many cases, but the paper does not give the claimed figure of about 30%. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, the action of esketamine on AMPA receptors may ultimately improve neural plasticity and synaptogenesis through signaling pathways resulting in enhanced BDNF production [62].”
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 3. Discussion
What the sources say
- Supportedcites [62] Salahudeen, 2020, Esketamine: New hope for the treatment of treatment-resistant depression? A narrative review, Ther. Adv. Drug Saf. source
The Pharmacology section states the claim almost verbatim, including its qualification that esketamine’s action on AMPA receptors may improve neural plasticity and synaptogenesis through signaling pathways that enhance BDNF production. (LLM, conf=0.95)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Peculiarly, a great majority of these TRD patients improve upon ketamine administration [27].”
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 3. Discussion
What the sources say
- Supportedcites [27] Serafini, 2014, The role of ketamine in treatment-resistant depression: A systematic review, Curr. Neuropharmacol. source
The Discussion states that ketamine has a rapid antidepressant effect in most TRD patients after a single infusion. The Results report response rates of 70.8%, 71%, and 91.6% in individual studies, supporting the claim that a large majority improve. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, in the cellular component category, neuron projections (GO:0043005), dendrites (GO:00340425), and ionotropic glutamate receptor complexes (GO:0008328) were the top enriched terms (Table 2).”
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 2. Results > 2.3. Gene Functional Enrichment Analysis
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, no differences were found regarding time to remission for any of the evaluated SNPs.”
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 2. Results > 2.2. Treatment Resistant Depression Phenotype
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 68 claims and to verify the 7 references still open.
- Probably not a substantial claim. 21
- It may state two separate claims as one. 16
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 3. Discussion
“Concerning SYN1 polymorphism rs114263, carriers of the GG genotype had a six-fold risk of presenting a TRD phenotype”
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 2. Results > 2.2. Treatment Resistant Depression Phenotype
“Additionally, there was a statistically significant association between rs1142636 of the SYN1 gene and TRD.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 4. Materials and Methods > 4.1. Patients
“Time to remission (TRD), time to relapse (TR), remission, and TRD were the evaluated AD treatment response phenotypes.”
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > Abstract
“Our results showed that BDNF rs6265, PTEN rs12569998, and SYN1 rs1142636 SNP were associated with treatment-resistant depression (TRD).”
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 1×
“In fact, the rs6265 (Val66Met) has been demonstrated to alter pro-BDNF processing and, consequently, the secretion of BDNF [10], as well as the hippocampal volume [11].”
BackgroundGene set knowledge discovery with enrichr
Xie, Z., Bailey, A., Kuleshov, M. V., Clarke, D. J. B., Evangelista, J. E., Jenkins, S. L., Lachmann, A., Wojciechowicz, M. L., Kropiwnicki, E., Jagodnik, K. M., et al. (2021) · Current Protocols · doi:10.1002/cpz1.90 · Cited by 3,451 · cited 1×
“…enrichment analysis together with the genes identified as associated with TRD in the present study (BDNF, SYN1, and PTEN) to perform GO and KEGG Pathway analyses with Enrichr (https://maayanlab.cloud/Enrichr/ accessed on 26 march 2023), according to the protocol described by Xie, 2021 et al. [68].”
MethodmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 7×
“Several polymorphisms in genes involved in several neurotrophic/neuroplasticity pathways were evaluated, namely BDNF (rs1491850, rs204946, rs6265, rs908867), CREB1 (rs11904814, rs2253206, rs6740584, rs889895), NTRK2 (rs1187323, rs1187326, rs1387926, rs1778929, rs1565445, rs1659412), NGFR (rs11466155, rs2072446, rs7341…”
BackgroundInfluentialA molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
SNP Genotyping Using the Sequenom MassARRAY iPLEX Platform
Gabriel, S., Ziaugra, L., & Tabbaa, D. (2009) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg0212s60 · Cited by 969
Castrén, E., & Rantamäki, T. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20758 · Cited by 864 · cited 1×
“The TrkB activation induces downstream pathways, including the PI3K/Akt pathway, which is linked to the Wnt/β-catenin and to the mTOR pathway [4,16].”
BackgroundEssential role of brain-derived neurotrophic factor in adult hippocampal function
Monteggia, L. M., Barrot, M., Powell, C. M., Berton, O., Galanis, V., Gemelli, T., Meuth, S., Nagy, A., Greene, R. W., & Nestler, E. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402141101 · Cited by 685
Role of neurotrophic factors in depression
CASTREN, E., VOIKAR, V, & RANTAMAKI, T. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.009 · Cited by 667
Glutamate and Neurotrophic Factors in Neuronal Plasticity and Disease
Mattson, M. P. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1418.005 · Cited by 640 · cited 1×
“These drugs are non-selective, non-competitive antagonists that block the NMDA receptor (an ionotropic glutamate receptor) on GABA interneurons, thereby increasing neurotrophic signaling that restores synaptic function [61].”
BackgroundPI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation
Peltier, J., O'Neill, A., & Schaffer, D. V. (2007) · Developmental Neurobiology · doi:10.1002/dneu.20506 · Cited by 443 · cited 1×
“The PI3K/Akt pathway has intrinsically an important role in promoting the proliferation of the adult hippocampal cell and also in the inhibition of cell differentiation [15,17].”
BackgroundCattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K. J., Craig, I. W., Anacker, C., Zunsztain, P. A., McGuffin, P., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.191 · Cited by 436
Zhou, W., Wang, N., Yang, C., Li, X.-M., Zhou, Z.-Q., & Yang, J.-J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.10.005 · Cited by 390
Short-term synaptic plasticity is altered in mice lacking synapsin I
Rosahl, T. (1993) · Cell · doi:10.1016/0092-8674(93)90487-b · Cited by 328 · cited 1×
“Therefore, it is likely that polymorphisms in synapsin I may affect axon elongation, branching, and synaptogenesis and play an ongoing role in the distribution of neurotransmitter vesicles and neurotransmitter release, and thus contribute to a TRD phenotype [41].”
BackgroundTrivedi, M. H., Rush, A. J., Crismon, M. L., Kashner, T. M., Toprac, M. G., Carmody, T. J., Key, T., Biggs, M. M., Shores-Wilson, K., Witte, B., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.669 · Cited by 316 · cited 2×
“Texas Medication Algorithm [65] was used to provide medications to the patients.”
MethodIn Vivo Regulation of Glycogen Synthase Kinase-3β (GSK3β) by Serotonergic Activity in Mouse Brain
Li, X., Zhu, W., Roh, M.-S., Friedman, A. B., Rosborough, K., & Jope, R. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300439 · Cited by 300 · cited 1×
“Additionally, treatment with AD was found to inhibit GSK3β activity in mouse brains [22], and genetic variations in GSK3B have been associated with response to selective serotonin reuptake inhibitor AD in Chinese MDD patients [23].”
BackgroundHosang, G. M., Shiles, C., Tansey, K. E., McGuffin, P., & Uher, R. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-7 · Cited by 292
Gourley, S. L., Wu, F. J., Kiraly, D. D., Ploski, J. E., Kedves, A. T., Duman, R. S., & Taylor, J. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.07.016 · Cited by 287
Zagrebelsky, M., Holz, A., Dechant, G., Barde, Y.-A., Bonhoeffer, T., & Korte, M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2492-05.2005 · Cited by 286 · cited 1×
“The activation of this receptor by pro-BDNF was demonstrated to induce neuronal atrophy and apoptosis, dendritic pruning, and the induction of long-term depression (LTD), opposed effects of the activation of TrkB by BDNF [14,15].”
BackgroundGong, R., Park, C. S., Abbassi, N. R., & Tang, S.-J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512524200 · Cited by 249 · cited 5×
“Several polymorphisms in genes involved in several neurotrophic/neuroplasticity pathways were evaluated, namely BDNF (rs1491850, rs204946, rs6265, rs908867), CREB1 (rs11904814, rs2253206, rs6740584, rs889895), NTRK2 (rs1187323, rs1187326, rs1387926, rs1778929, rs1565445, rs1659412), NGFR (rs11466155, rs2072446, rs7341…”
BackgroundInfluentialNeurotrophic effects of antidepressant drugs
CASTREN, E. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.10.004 · Cited by 244 · cited 1×
“The clinical AD response develops slowly over the first weeks of treatment, and one explanation for this delayed response may be the need for physical growth and reorganization in the brain, responses that are mediated by BDNF signaling and downstream pathway events [2].”
BackgroundThe role of ketamine in treatment-resistant depression: A systematic review
Serafini, G., Howland, R., Rovedi, F., Girardi, P., & Amore, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140619204251 · Cited by 234 · cited 2×
“improve upon ketamine administration [27].”
BackgroundTsai, S., Cheng, C., Yu, Y. W., Chen, T., & Hong, C. (2003) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20026 · Cited by 214
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
Kwok, J. B. J., Hallupp, M., Loy, C. T., Chan, D. K. Y., Woo, J., Mellick, G. D., Buchanan, D. D., Silburn, P. A., Halliday, G. M., & Schofield, P. R. (2005) · Annals of Neurology · doi:10.1002/ana.20691 · Cited by 205 · cited 1×
“In vitro data have demonstrated that GSK3B (rs6438552) intronic polymorphism regulates the selection of splice acceptor sites and thus alters GSK3β transcription [35].”
BackgroundIdentification of a mutation in synapsin I, a synaptic vesicle protein, in a family with epilepsy
Garcia, C. C., Blair, H. J., Seager, M., Coulthard, A., Tennant, S., Buddles, M., Curtis, A., & Goodship, J. A. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.013680 · Cited by 205 · cited 3×
“The putative influence of SYN1 in TRD patients may be related to the fact that synapsins play a role during neuronal development and synapse formation [39,40].”
BackgroundDiscovery and validation of blood biomarkers for suicidality
Le-Niculescu, H., Levey, D. F., Ayalew, M., Palmer, L., Gavrin, L. M., Jain, N., Winiger, E., Bhosrekar, S., Shankar, G., Radel, M., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.95 · Cited by 193 · cited 1×
“Regarding PTEN, this gene has been reported as a biomarker of a high versus low suicidality state [42], although a subsequent report did not corroborate the findings [43].”
ResultCorreia-Melo, F. S., Leal, G. C., Vieira, F., Jesus-Nunes, A. P., Mello, R. P., Magnavita, G., Caliman-Fontes, A. T., Echegaray, M. V. F., Bandeira, I. D., Silva, S. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.086 · Cited by 193 · cited 1×
“This is consistent with the mechanism of action of ketamine and esketamine, two drugs that have shown efficacy in TRD patients [60].”
ResultZubenko, G. S., Maher, B., Hughes, H. B., Zubenko, W. N., Stiffler, J. S., Kaplan, B. B., & Marazita, M. L. (2003) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20073 · Cited by 191 · cited 1×
“Moreover, a chromosomal region of 2q33–35, which included this gene, has been associated with mood disorders [19].”
BackgroundDong, C., Wong, M.-L., & Licinio, J. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.92 · Cited by 182 · cited 1×
“NTRK2 gene polymorphism has been associated with an increased risk of developing Treatment Resistant Depression (TRD) [12], with a reduction of HAM-D21 score [13].”
BackgroundChoi, M.-J., Kang, R.-H., Lim, S.-W., Oh, K.-S., & Lee, M.-S. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.012 · Cited by 180
MAP Kinase Activation by Fluoxetine and Its Relation to Gene Expression in Cultured Rat Astrocytes
Mercier, G., Lennon, A. M., Renouf, B., Dessouroux, A., Ramaugé, M., Courtin, F., & Pierre, M. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:2:207 · Cited by 176 · cited 2×
“tion of glial cell line-derived neurotrophic factor [33].”
BackgroundThe effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels
Ozan, E., Okur, H., Eker, M. C., Eker, Ö. D., Gönül, A. S., & Akarsu, N. A. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.06.022 · Cited by 143
Distinct Roles of Synapsin I and Synapsin II during Neuronal Development
Ferreira, A., Chin, L.-S., Li, L., Lanier, L. M., Kosik, K. S., & Greengard, P. (1998) · Molecular Medicine · doi:10.1007/bf03401726 · Cited by 131 · cited 2×
“The putative influence of SYN1 in TRD patients may be related to the fact that synapsins play a role during neuronal development and synapse formation [39,40].”
BackgroundASsociation of gsk3β polymorphisms with brain structural changes in major depressive disorder
Inkster, B., Nichols, T. E., Saemann, P. G., Auer, D. P., Holsboer, F., Muglia, P., & Matthews, P. M. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.70 · Cited by 127 · cited 2×
“with brain structural changes in MDD [36,37].”
BackgroundBrain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response
Domschke, K., Lawford, B., Laje, G., Berger, K., Young, R., Morris, P., Deckert, J., Arolt, V., McMahon, F. J., & Baune, B. T. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000030 · Cited by 122 · cited 1×
“[50], showed a better response in the rs6265 Val/Val genotype, others found a more favorable outcome in Met allele carriers [51–53].”
BackgroundRibeiro, L., Busnello, J. V., Cantor, R. M., Whelan, F., Whittaker, P., Deloukas, P., Wong, M.-L., & Licinio, J. (2007) · NeuroReport · doi:10.1097/wnr.0b013e328273bcb0 · Cited by 101
Dwivedi, Y., Rizavi, H. S., Zhang, H., Roberts, R. C., Conley, R. R., & Pandey, G. N. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990575 · Cited by 101 · cited 2×
“In fact, depression was previously associated with an aberrant MAPK1 signaling pathway [34].”
BackgroundBDNF Val66met polymorphism, white matter abnormalities and remission of geriatric depression
Alexopoulos, G. S., Glatt, C. E., Hoptman, M. J., Kanellopoulos, D., Murphy, C. F., Kelly, R. E., Morimoto, S. S., Lim, K. O., & Gunning, F. M. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.02.115 · Cited by 97
Geneshot: search engine for ranking genes from arbitrary text queries
Lachmann, A., Schilder, B. M., Wojciechowicz, M. L., Torre, D., Kuleshov, M. V., Keenan, A. B., & Ma’ayan, A. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz393 · Cited by 91
Pilar-Cuéllar, F., Vidal, R., Díaz, A., Castro, E., dos Anjos, S., Pascual-Brazo, J., Linge, R., Vargas, V., Blanco, H., Martínez-Villayandre, B., et al. (2013) · Neural Plasticity · doi:10.1155/2013/537265 · Cited by 90 · cited 11×
“AD also produces increased Akt levels in several brain structures, including the hippocampus [18] and prefrontal cortex [15].”
BackgroundInfluentialNeuroimaging genetics: New perspectives in research on major depression?
Frodl, T., Möller, H. ‐., & Meisenzahl, E. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01225.x · Cited by 87
Depression, the Val66Met polymorphism, age, and gender influence the serum BDNF level
Elfving, B., Buttenschøn, H. N., Foldager, L., Poulsen, P. H. P., Andersen, J. H., Grynderup, M. B., Hansen, Å. M., Kolstad, H. A., Kærlev, L., Mikkelsen, S., et al. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.05.003 · Cited by 81
No effect of 5HTTLPR or BDNF Val66Met polymorphism on hippocampal morphology in major depression
Cole, J., Weinberger, D. R., Mattay, V. S., Cheng, X., Toga, A. W., Thompson, P. M., Powell-Smith, G., Cohen-Woods, S., Simmons, A., McGuffin, P., et al. (2011) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2011.00714.x · Cited by 81
Yoshida, K., Higuchi, H., Kamata, M., Takahashi, H., Inoue, K., Suzuki, T., Itoh, K., & Ozaki, N. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106072192 · Cited by 80
Serotonin and neuronal growth factors—a convergence of signaling pathways
Cowen, D. S. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04420.x · Cited by 72 · cited 1×
“The TrkB activation induces downstream pathways, including the PI3K/Akt pathway, which is linked to the Wnt/β-catenin and to the mTOR pathway [4,16].”
BackgroundEsketamine: new hope for the treatment of treatment-resistant depression? A narrative review
Salahudeen, M. S., Wright, C. M., & Peterson, G. M. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620937899 · Cited by 72
Tsai, S.-J., Liou, Y.-J., Hong, C.-J., Yu, Y. W.-Y., & Chen, T.-J. (2008) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500486 · Cited by 66 · cited 1×
“Additionally, treatment with AD was found to inhibit GSK3β activity in mouse brains [22], and genetic variations in GSK3B have been associated with response to selective serotonin reuptake inhibitor AD in Chinese MDD patients [23].”
BackgroundLi, Z., Zhang, Y., Wang, Z., Chen, J., Fan, J., Guan, Y., Zhang, C., Yuan, C., Hong, W., Wang, Y., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.10.003 · Cited by 63 · cited 1×
“NTRK2 gene polymorphism has been associated with an increased risk of developing Treatment Resistant Depression (TRD) [12], with a reduction of HAM-D21 score [13].”
BackgroundKang, R., Chang, H., Wong, M., Choi, M., Park, J., Lee, H., Jung, I., Joe, S., Kim, L., Kim, S., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109105457 · Cited by 55
Chi, M. H., Chang, H. H., Lee, S.-Y., Lee, I. H., Gean, P. W., Yang, Y. K., Lu, R., & Chen, P. S. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.07.006 · Cited by 54
Interacting effect of BDNF Val66Met polymorphism and stressful life events on adolescent depression
Chen, J., Li, X., & McGue, M. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00843.x · Cited by 52
liu, Z., Guo, H., Cao, X., Cheng, C., Yang, C., Xu, C., Zhang, A., Sun, N., Li, X., & Zhang, K. (2014) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2014.05.010 · Cited by 50 · cited 2×
“with brain structural changes in MDD [36,37].”
BackgroundBDNF Val66Met genotype and 6-month remission rates in late-life depression
Taylor, W. D., McQuoid, D. R., Ashley-Koch, A., MacFall, J. R., Bridgers, J., Krishnan, R. R., & Steffens, D. C. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.12 · Cited by 50
Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine
Hashimoto, K. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.176 · Cited by 47
A role for nuclear β-catenin in SNRI antidepressant-induced hippocampal cell proliferation
Mostany, R., Valdizán, E. M., & Pazos, A. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.04.012 · Cited by 47
Calati, R., Crisafulli, C., Balestri, M., Serretti, A., Spina, E., Calabrò, M., Sidoti, A., Albani, D., Massat, I., Höfer, P., et al. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.03.005 · Cited by 45 · cited 2×
“This polymorphism has been previously studied in MDD patients and was not associated with treatment resistance, response, and remission, but its relation with relapse was not determined [20].”
BackgroundChen, J., Li, X., & McGue, M. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12099 · Cited by 40
Deng, F., Tan, L., Shen, H., Liu, Y., Liu, Y., Li, J., Zhu, X.-Z., Chen, X., Tian, Q., Zhao, M., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1997 · Cited by 35
Investigation of blood mRNA biomarkers for suicidality in an independent sample
Mullins, N., Hodgson, K., Tansey, K. E., Perroud, N., Maier, W., Mors, O., Rietschel, M., Hauser, J., Henigsberg, N., Souery, D., et al. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.112 · Cited by 30 · cited 1×
“Regarding PTEN, this gene has been reported as a biomarker of a high versus low suicidality state [42], although a subsequent report did not corroborate the findings [43].”
ResultMusil, R., Zill, P., Seemüller, F., Bondy, B., Obermeier, M., Spellmann, I., Bender, W., Adli, M., Heuser, I., Zeiler, J., et al. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0364-1 · Cited by 27
Quest for biomarkers of treatment-resistant depression: Shifting the paradigm toward risk
Smith, D. F. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00057 · Cited by 22 · cited 1×
“In addition to the lag time between AD and clinical improvement, there are still about 30% of MDD patients who do not present improvements upon AD treatment, displaying a TRD phenotype [26].”
BackgroundLiu, S., Sun, N., Xu, Y., Yang, C., Ren, Y., Liu, Z., Cao, X., Sun, Y., Xu, Q., Zhang, K., et al. (2012) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0227 · Cited by 21 · cited 1×
“Likewise, much interest has been given to the glycogen synthase kinase-3β (GSK3β), a key regulator of neuronal function [21].”
BackgroundZou, Y., Wang, Y., Liu, P., Feng, X., Wang, B., Zang, T., Yu, X., Wei, J., Liu, Z., Liu, Y., et al. (2010) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1099 · Cited by 21
Lemos, J. C., Roth, C. A., & Chavkin, C. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-024-9_11 · Cited by 16 · cited 2×
“It is known that MAPK1 activation is altered after stress [31] and corti-”
BackgroundKetamine modifies mood through mTOR
Welberg, L. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2916 · Cited by 16
FAS -670A>G genetic polymorphism Is associated with Treatment Resistant Depression
Santos, M., Carvalho, S., Lima, L., Mota-Pereira, J., Pimentel, P., Maia, D., Correia, D., Gomes, S., Cruz, A., & Medeiros, R. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.06.027 · Cited by 12 · cited 2×
“The participants of this study were 80 MDD patients (followed by 27 months) from a cohort recruited at Hospital Magalhães Lemos, Oporto, Portugal, as we previously described [63,64].”
BackgroundMethodSelf-citationSantos, M., Carvalho, S., Lima, L., Mota-Pereira, J., Pimentel, P., Maia, D., Correia, D., Gomes, S., Cruz, A., & Medeiros, R. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.03.026 · Cited by 10 · cited 1×
“The participants of this study were 80 MDD patients (followed by 27 months) from a cohort recruited at Hospital Magalhães Lemos, Oporto, Portugal, as we previously described [63,64].”
MethodSelf-citationYu, G. I., Kim, S. K., Park, H. J., Kim, J. W., Chung, J., & Shin, D. H. (2012) · Synapse · doi:10.1002/syn.21583 · Cited by 3 · cited 1×
“SYN1 polymorphism has been previously evaluated in schizophrenia, and the G allele of synonymous SNP (rs1142636, Asn170Asn) in SYN1 was found to be a risk factor for schizophrenia susceptibility in Korean female patients [38].”
Background
Research works printed but not linked: 1
- Gabriel, S., Ziaugra, L., and Tabbaa, D. (2001). Current Protocols in Human Genetics, John Wiley & Sons, Inc.
Cited by
From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine
Toader, C., Șerban, M., Munteanu, O., Covache-Busuioc, R.-A., Enyedi, M., Ciurea, A. V., & Tătaru, C. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094271 · Cited by 184
Numakawa, T., & Kajihara, R. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1247422 · Cited by 96
Jain, N. K., Tailang, M., Chandrasekaran, B., Khazaleh, N., Thangavel, N., Makeen, H. A., Albratty, M., Najmi, A., Alhazmi, H. A., Zoghebi, K. A., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1290398 · Cited by 44
Liu, J., Zhou, S., Wang, Y., Liu, J., Sun, S., Sun, Y., Xu, P., Xu, X., Zhu, B., & Wu, H. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116604 · Cited by 20
Minbay, M., Khan, A., Ghasemi, A. R., Ingram, K. K., & Ay, A. A. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115948 · Cited by 16
Metadata
- Authors
- Santos, M., Lima, L., Carvalho, S., Mota-Pereira, J., Pimentel, P., Maia, D., Correia, D., Barroso, M. F., Gomes, S., Cruz, A., & Medeiros, R.
- Affiliations
- IPO Porto (PT)
- Experimental Pathology and Therapeutics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072 Porto, Portugal
- Hospital de Magalhães Lemos (PT)
- Clínica Médico-Psiquiátrica da Ordem, 4000-270 Porto, Portugal
- Unidade Local de Saúde de Trás-os-Montes e Alto Douro (PT)
- Rede de Química e Tecnologia (PT)
- Centro de Investigação em Saúde e Ambiente (PT)
- Corresponding author
- Santos, Marlene
- Medeiros, Rui
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-04-04
- Volume
- 24
- Issue
- 7
- Pages
- 6758
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10095078
- OpenAlex
- W4362620113
- Cited by
- 20
- References
- 70
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 8 · 2023: 3
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
- Funders
- AstraZeneca Foundation
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- antidepressant response, treatment-resistant depression, major depressive disorder, genetic polymorphism, brain-derived neurotrophic factor, NTRK2, nerve growth factor receptor, CREB1, GSK3B, Akt, MAPK1, mTOR, PTEN, Arc, synapsin I, relapse, neuroplasticity, BDNF/TrkB signaling, mTOR signaling, ERK signaling, synaptic transmission, predictive biomarkers
- MeSH terms
- Glycogen Synthase Kinase 3 beta, Antidepressive Agents, Major Depressive Disorder, Humans, Nerve Tissue Proteins, Phenotype, Recurrence, Cyclic AMP Response Element-Binding Protein, Receptors, Nerve Growth Factor, Brain-Derived Neurotrophic Factor, Mitogen-Activated Protein Kinase 1, Polymorphism, Single Nucleotide, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.